Search Results
201 results found-
CSL Seqirus provides innovative solutions for pandemic preparedness and response.
https://www.csl.com/patients-public-health/vaccines/pandemic-response -
CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
Steve Marlow, CSL Seqirus General Manager, added "Importantly, it is another step towards our long-term aim to advance public health by developing and commercializing enhanced vaccines for influenza and multi-pathogen pandemic preparedness.
https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology -
CSL Seqirus is a global influenza vaccine provider developing innovative solutions.
https://www.csl.com/patients-public-health/vaccines -
CSL is committed to pricing practices that reflect the value our products bring to patients and society.
https://www.csl.com/sustainability/social/access-and-health-security -
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health -
We are a diverse collective of people after one goal - to reimagine, reinvent and find new answers that save, improve and protect life.
https://www.csl.com/we-are-csl -
CSL's is recognized for our contributions to developing breakthrough medicines that have the potential to help millions of patients worldwide.
https://www.csl.com/research-and-development/r-and-d-capabilities -
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
https://newsroom.csl.com/2022-10-05-CSL-Announces-Positive-Preclinical-Data-for-Self-Amplifying-Messenger-RNA-sa-mRNA-Influenza-Vaccine-Candidates